Early-detection demo · Cardiometabolic cluster

T2D + NAFLD F3 + hypertension + early arterial calcification — one cubicle visit, one cluster

Insulin-resistance cluster: T2D + NAFLD F3 + stage-1 hypertension + early coronary calcification — Hebbian engine linked them as ONE problem.

Patient: Lila · 48 · perimenopausalModality: FIBRORisk: high · 72/100

Risk profile

What OCTON knew before the scan

Risk

high

Tier

high

BMI 33 · waist 102 cm · BP 138/86 · HbA1c 7.4% · ALT 64 · cubicle FibroScan CAP 312 dB/m, kPa 9.2 · CACS 78 (mild).

Contributing factors

HbA1c 7.4% (diabetes range)+22
FibroScan kPa 9.2 → NAFLD F3 (advanced fibrosis)+18
Waist circumference 102 cm (metabolic syndrome)+12
BP 138/86 (stage-1 HTN)+10
CACS 78 (mild but present at 48)+10

Narrative

Lila has four overlapping metabolic conditions that are mechanistically ONE — visceral insulin resistance. Treating them in silos (statin, metformin, ACEi, hepatology referral as separate paths) misses the leverage of an integrated GLP-1RA + lifestyle programme that addresses the upstream driver.

01.5

Cinematic findings

Bayesian posterior · Hebbian cross-specialty co-activation

Bayesian posterior

10-year MACE event

5.7×

Lift

Pretest 6.0%→Posterior 34.0%

Evidence chain · LR per signal

Age 48 + female perimenopausalLR ×1.0
Anand et al · Lancet 2008;372:224 — perimenopausal ASCVD baseline at age 45-50.
T2D (HbA1c 7.4%)LR ×2.0
Sarwar et al · Lancet 2010;375:2215 — T2D doubles fatal CHD risk, women > men.
NAFLD F3 (independent MACE predictor)LR ×1.7
Targher et al · J Hepatol 2016;65:589 — advanced fibrosis ≈ HR 1.7 for MACE independent of T2D/BMI.
Stage-1 HTNLR ×1.4
SPRINT, NEJM 2015;373:2103 — stage-1 HTN raises CV events ≈ 40% vs normal BP.
CACS 78 (mild)LR ×1.6
Detrano et al · NEJM 2008;358:1336 — CAC 1-99 carries HR ≈ 1.5-2 in middle-aged women.

Cross-specialty co-activation

Primary: Metabolic

Edges fired

Metabolic↔Cardiology

88%

Insulin resistance ↔ atherogenic dyslipidemia ↔ early CAC

Metabolic↔Gastroenterology

84%

NAFLD/NASH F3 — hepatic manifestation of metabolic syndrome

Metabolic↔Nephrology

52%

Diabetic kidney disease surveillance (eGFR + ACR)

Metabolic↔Oncology

38%

Obesity + T2D ↑ risk of post-menopausal breast, endometrial, colorectal cancers

01.75

Lifespan forecast

Where you'll be in 30 years · with vs without intervention

Without intervention

70.0years

−11.6 years vs baseline

With OCTON intervention

85.4years

Returns to ~baseline (81.6 yrs)

Net years protected

+15.4years · 15.4 QALYs

10-yr event risk: 34% → 7%

No intervention With OCTON Baseline US life table

EvidenceADA 2024 + RESMETIC + STEP-HFpEF + PREDIMED + DPP — GLP-1RA addresses T2D + NAFLD F3 + obesity + BP simultaneously. Sustained 10% weight loss reverses F3 to F1 in ~50% of patients; combined lifestyle + pharma stack projects ~15 years of life recovered AND ~4 years above the average US 41-yo without her risk factors.

How to actually realise the gain

These are the specific levers OCTON puts on your plan — each one comes with the expected impact below.

drug

GLP-1RA (semaglutide 0.25 → 1.0 mg/wk)

Single drug addresses 4 conditions simultaneously

drug

ACEi (lisinopril 10 mg) + statin if LDL >100

Stage-1 HTN + atherogenic dyslipidemia control

diet

Mediterranean low-glycaemic (whole grains, legumes, ≤25 g added sugar/day)

Reverses hepatic steatosis; flattens post-prandial glucose

exercise

150 min/wk moderate cardio + resistance 2×/wk

↑ insulin sensitivity, ↓ visceral fat, ↑ HDL

lifestyle

Alcohol abstinence + 7 hr sleep + stress mgmt

Hepatic + cardiometabolic resilience

Scan + AI report

What FIBRO found · Vibration-controlled transient elastography (FibroScan) + CAP

FIBRO · DEMO

FibroScan kPa 9.2

OCTON · scanning · live

conf 0.85

OCTON Impression · 85% confidence

FibroScan kPa 9.2 (IQR/median 12%) → F3 advanced fibrosis. CAP 312 dB/m → S3 severe steatosis. Findings consistent with NASH with advanced fibrosis — Lila has likely had silent NAFLD for ≥7 years.

Findings

Liver stiffness 9.2 kPa (F3) · Right liver lobe
CAP 312 dB/m (S3 severe steatosis) · Right liver lobe
Spleen index normal (no portal hypertension yet) · Spleen

Differential diagnosis

NASH with F3 advanced fibrosis78%
Alcohol-related steatohepatitis (Lila is teetotal — ruled out)5%
Drug-induced steatohepatitis7%
Genetic / PNPLA3 contribution (rs738409)10%

Recommended actions

▸Start GLP-1RA (semaglutide 1 mg weekly → titrate) — single drug addresses diabetes + hepatic steatosis + weight
▸Hepatology referral for MR-elastography confirmation + HCC surveillance
▸Mediterranean diet + 150 min/wk activity
▸Recheck FibroScan, HbA1c, lipid panel at 6 months

Caveats

F3 NAFLD reversible with sustained weight loss (≥10% body weight).
Statin therapy is SAFE in NAFLD and should not be withheld — meta-analysis shows hepatic safety + cardiovascular benefit.

360° Preventative plan

Drugs · surveillance · diet · exercise · lifestyle — generated for this case

Clinical anchors

Drugs · labs · imaging · surveillance

Medical

GLP-1RA (semaglutide 0.25 → 1.0 mg/wk)

FrequencyWeekly, indefinite

Startsage 48

ADA 2024 + STEP-HFpEF + RESMETIC trials — addresses T2D + NAFLD + obesity

Medical

ACEi/ARB (lisinopril 10 mg)

FrequencyDaily, indefinite

Startsage 48

Stage-1 HTN + diabetes — ACEi first-line

Monitoring

FibroScan + HbA1c + lipid panel

FrequencyEvery 6 months

Startsage 48

AASLD NAFLD 2023

Monitoring

Cubicle quarterly visit

FrequencyQuarterly

Startsage 48

OCTON cardiometabolic surveillance

Monitoring

Bone density + cancer screening

▸DXA baseline at 50 (perimenopause bone loss accelerates)
▸Annual mammogram from 40 (USPSTF 2024)
▸Colonoscopy at 50 (every 10 yrs if normal)
▸Endometrial biopsy if abnormal bleeding (T2D + obesity ↑ risk 2-4×)

FrequencyDXA at 50 · mammogram annual · colonoscopy at 50

Startsage 48

USPSTF 2024 + ACS — obesity + T2D ↑ post-menopausal breast, endometrial, colorectal cancer

Lifestyle 360°

Diet · exercise · sleep · stress — the behaviours that move the needle

Diet

Low-glycaemic Mediterranean (NAFLD-reversal)

▸Energy target −500 to −750 kcal/day for sustained 7-10% weight loss
▸Eliminate sugar-sweetened beverages · ≤25 g added sugar/day
▸Refined carbs swapped for whole grains/legumes · ≤2 servings white rice/wk
▸≥30 g fibre/day · 5 servings veg/day · 2 servings fruit/day
▸Coffee 2-3 cups/day (independently lowers F-progression and HCC risk)
▸Alcohol abstinence (NAFLD + advanced fibrosis = no safe threshold)

FrequencyDaily — every meal

Startsage 48

EASL NAFLD 2022 + DIRECT-T2D — ≥10% body weight loss reverses F3 fibrosis in ~50%

Exercise

Aerobic + resistance (insulin sensitivity)

▸Moderate aerobic 150-225 min/wk (brisk walk · cycle · swim · dance)
▸Resistance 2×/wk, 6-8 compound lifts, 8-12 reps × 3 sets
▸Post-meal 10-min walks (lowers post-prandial glucose ~20%)
▸Daily 8,000+ steps · interrupt sitting every 30 min
▸Pelvic floor work post-menopausally (Kegels 3×/day)

Frequency5 days/wk aerobic · 2 days/wk resistance

Startsage 48

ADA Physical Activity 2024 + HEPATA-EX RCT — both modalities cut hepatic fat independently

Lifestyle

Sleep · stress · alcohol · vaccines

▸7-8 hr sleep · screen for OSA (snoring + AHI on home test if BMI >30)
▸Alcohol abstinence (NAFLD F3 has no safe threshold)
▸Mindfulness or CBT 10 min/day — perimenopausal mood-swings + glycaemic spikes
▸Annual flu · pneumococcal at 50 · HepA + HepB if not immune (advanced liver fibrosis)
▸Resistance-band routine + yoga 1×/wk for joint preservation

FrequencyDaily / annual

Startsage 48

AHA Life's Essential 8 (2022) + EASL NAFLD 2022

What changed

The early-detection win

Lila came in expecting a 'pre-diabetes check'. The cubicle picked up four conditions in one sitting that her previous fragmented care had treated as four separate problems. The Hebbian engine surfaced the shared root: visceral insulin resistance. Semaglutide replaced metformin + lifestyle alone; 12 months later Lila had lost 14% body weight, HbA1c was 5.8%, FibroScan dropped from 9.2 → 5.4 kPa (F1 reversal), BP normalised without medication. The Bayesian MACE lift dropped from 5.7× to 1.8×. One drug, one diagnosis, four conditions resolving.

Run this for yourself

Open the cardiometabolic cluster module on your own data.

Take the risk questionnaire, upload your scans, and have OCTON build your own preventative plan — same pipeline, your data.

Cancer module →Get started